BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 10148675)

  • 1. A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs.
    Pelletier KR
    Am J Health Promot; 1991; 5(4):311-3. PubMed ID: 10148675
    [No Abstract]   [Full Text] [Related]  

  • 2. Worksite economical setting for preventive health care programs.
    Polakoff PL
    Occup Health Saf; 1985 Jun; 54(6):75-6. PubMed ID: 4022527
    [No Abstract]   [Full Text] [Related]  

  • 3. Conceptual framework, critical questions, and practical challenges in conducting research on the financial impact of worksite health promotion.
    Anderson DR; Serxner SA; Gold DB
    Am J Health Promot; 2001; 15(5):281-8. PubMed ID: 11502010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical preventive medicine in business and industry: the economic impact.
    Blake GH; DeHart RL
    J Health Soc Policy; 1994; 6(1):59-70. PubMed ID: 10140440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Economic aspects of prevention: an international perspective].
    Suhrcke M
    Gesundheitswesen; 2009 Oct; 71(10):610-6. PubMed ID: 19885761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of health promotion programs.
    Harris JS
    J Occup Med; 1991 Mar; 33(3):327-30. PubMed ID: 1903155
    [No Abstract]   [Full Text] [Related]  

  • 7. The financial impact of health promotion and disease prevention programs--why is it so hard to prove value?
    Goetzel RZ
    Am J Health Promot; 2001; 15(5):277-80. PubMed ID: 11502009
    [No Abstract]   [Full Text] [Related]  

  • 8. Occupational health-promotion programs: evaluation efforts and measured cost savings.
    Katzman MS; Smith KJ
    Health Values; 1989; 13(2):3-10. PubMed ID: 10312913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing need and demand.
    Fries JF
    Healthc Forum J; 1993; 36(6):18-23. PubMed ID: 10129746
    [No Abstract]   [Full Text] [Related]  

  • 10. Getting closer to the truth: overcoming research challenges when estimating the financial impact of worksite health promotion programs.
    Ozminkowski RJ; Goetzel RZ
    Am J Health Promot; 2001; 15(5):289-95. PubMed ID: 11502011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial impact of health promotion: we need to know much more, but we know enough to act.
    Harris JR; Holman PB; Carande-Kulis VG
    Am J Health Promot; 2001; 15(5):378-82. PubMed ID: 11502028
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention: is there value for corporate purchasers?
    Kerr VE
    Am J Health Promot; 2001; 15(5):360-1. PubMed ID: 11502019
    [No Abstract]   [Full Text] [Related]  

  • 13. A review and analysis of the clinical and cost-effectiveness studies of comprehensive health promotion and disease management programs at the worksite: 1995-1998 update (IV).
    Pelletier KR
    Am J Health Promot; 1999; 13(6):333-45, iii. PubMed ID: 10557506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating worksite health programs.
    Gehlbach SH; Mundt KA
    J Ambul Care Manage; 1994 Apr; 17(2):82-91. PubMed ID: 10133291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs at the worksite: 1993-1995 update.
    Pelletier KR
    Am J Health Promot; 1996; 10(5):380-8. PubMed ID: 10163308
    [No Abstract]   [Full Text] [Related]  

  • 16. Estimating the effectiveness and efficiency of US HIV prevention efforts using scenario and cost-effectiveness analysis.
    Holtgrave DR
    AIDS; 2002 Nov; 16(17):2347-9. PubMed ID: 12441812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The power of prevention and what it requires.
    Woolf SH
    JAMA; 2008 May; 299(20):2437-9. PubMed ID: 18505953
    [No Abstract]   [Full Text] [Related]  

  • 18. [What to evaluate in prevention outcomes: Effectiveness, Cost-benefits, Cost-savings, Equity].
    Cislaghi C
    Epidemiol Prev; 2018; 42(5-6):372-375. PubMed ID: 30370741
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic analysis of preventive medicine in Japan--based on two empirical studies.
    Kawabuchi K
    Jpn Hosp; 1997 Jul; 16():55-62. PubMed ID: 10174051
    [No Abstract]   [Full Text] [Related]  

  • 20. Lifestyle modification interventions and cardiovascular health: global perspectives on worksite health and wellness and cardiac rehabilitation.
    Arena R
    Prog Cardiovasc Dis; 2014; 56(5):473-5. PubMed ID: 24607010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.